abiraterone acetate / Generic mfg. - LARVOL DELTA

Tolerability of Doublet Therapy in Elderly (≥75 years) with Metastatic Prostate Cancer: A Single Centre Experience study (SIOG 2025) - "ARPIs used included 44% darolutamide , 31% abiraterone, 11% enzalutamide and 14% apalutamide. These findings highlight the feasibility and tolerability of doublet therapy in elderly patients, emphasising its role in improving outcomes in a real-world setting."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Beyond the Trial: Real-World Insights into Fracture Risk among Patients with Advanced Prostate Cancer (SIOG 2025) - " This population-based cohort study consisted of eligible patients identified from the SEER-Medicare files who received abiraterone with prednisone (AAP) or enzalutamide (ENZA) in 2013-2020. The fracture risk after ARPI observed in this real-world study is significantly higher than in the randomized trials and underscores the urgent need for early identification and intervention of individuals at high risk of fracture."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Early Unplanned Hospitalization Risk After Novel Hormonal Therapy Initiation in Metastatic Prostate Cancer: Impact of Disease Type, Treatment, and Race (SIOG 2025) - "Objective: To quantify early UH incidence after initiating PC therapies, abiraterone acetate + prednisone (AAP) or enzalutamide (ENZA), assessing differences by disease stage and race. Early UH risk after initiating PC therapies varies markedly by disease type, treatment choice, and race. This highlights the need for close clinical monitoring and supportive care strategies to mitigate hospitalization risks during treatment. While there is some increase in white men; clinical algorithms should be similar across all groups."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Tolerability of Doublet Therapy in Elderly (≥75 years) with Metastatic Prostate Cancer: A Single Centre Experience study (SIOG 2025) - "ARPIs used included 44% darolutamide , 31% abiraterone, 11% enzalutamide and 14% apalutamide. These findings highlight the feasibility and tolerability of doublet therapy in elderly patients, emphasising its role in improving outcomes in a real-world setting."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Tolerability of Doublet Therapy in Elderly (≥75 years) with Metastatic Prostate Cancer: A Single Centre Experience study (SIOG 2025) - "ARPIs used included 44% darolutamide , 31% abiraterone, 11% enzalutamide and 14% apalutamide. These findings highlight the feasibility and tolerability of doublet therapy in elderly patients, emphasising its role in improving outcomes in a real-world setting."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Beyond the Trial: Real-World Insights into Fracture Risk among Patients with Advanced Prostate Cancer (SIOG 2025) - " This population-based cohort study consisted of eligible patients identified from the SEER-Medicare files who received abiraterone with prednisone (AAP) or enzalutamide (ENZA) in 2013-2020. The fracture risk after ARPI observed in this real-world study is significantly higher than in the randomized trials and underscores the urgent need for early identification and intervention of individuals at high risk of fracture."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Early Unplanned Hospitalization Risk After Novel Hormonal Therapy Initiation in Metastatic Prostate Cancer: Impact of Disease Type, Treatment, and Race (SIOG 2025) - "Objective: To quantify early UH incidence after initiating PC therapies, abiraterone acetate + prednisone (AAP) or enzalutamide (ENZA), assessing differences by disease stage and race. Early UH risk after initiating PC therapies varies markedly by disease type, treatment choice, and race. This highlights the need for close clinical monitoring and supportive care strategies to mitigate hospitalization risks during treatment. While there is some increase in white men; clinical algorithms should be similar across all groups."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Evaluation and Comparison of Abiraterone Dosing (250 mg vs 1000 mg) Daily in Prostate Cancer Patients at Cincinnati Veterans Affairs Medical Center (CVAMC) (ASHP 2025) - No abstract available

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Early Unplanned Hospitalization Risk After Novel Hormonal Therapy Initiation in Metastatic Prostate Cancer: Impact of Disease Type, Treatment, and Race (SIOG 2025) - "Objective: To quantify early UH incidence after initiating PC therapies, abiraterone acetate + prednisone (AAP) or enzalutamide (ENZA), assessing differences by disease stage and race. Early UH risk after initiating PC therapies varies markedly by disease type, treatment choice, and race. This highlights the need for close clinical monitoring and supportive care strategies to mitigate hospitalization risks during treatment. While there is some increase in white men; clinical algorithms should be similar across all groups."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Early Unplanned Hospitalization Risk After Novel Hormonal Therapy Initiation in Metastatic Prostate Cancer: Impact of Disease Type, Treatment, and Race (SIOG 2025) - "Objective: To quantify early UH incidence after initiating PC therapies, abiraterone acetate + prednisone (AAP) or enzalutamide (ENZA), assessing differences by disease stage and race. Early UH risk after initiating PC therapies varies markedly by disease type, treatment choice, and race. This highlights the need for close clinical monitoring and supportive care strategies to mitigate hospitalization risks during treatment. While there is some increase in white men; clinical algorithms should be similar across all groups."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Beyond the Trial: Real-World Insights into Fracture Risk among Patients with Advanced Prostate Cancer (SIOG 2025) - " This population-based cohort study consisted of eligible patients identified from the SEER-Medicare files who received abiraterone with prednisone (AAP) or enzalutamide (ENZA) in 2013-2020. The fracture risk after ARPI observed in this real-world study is significantly higher than in the randomized trials and underscores the urgent need for early identification and intervention of individuals at high risk of fracture."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Beyond the Trial: Real-World Insights into Fracture Risk among Patients with Advanced Prostate Cancer (SIOG 2025) - " This population-based cohort study consisted of eligible patients identified from the SEER-Medicare files who received abiraterone with prednisone (AAP) or enzalutamide (ENZA) in 2013-2020. The fracture risk after ARPI observed in this real-world study is significantly higher than in the randomized trials and underscores the urgent need for early identification and intervention of individuals at high risk of fracture."

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Assessment of Healthcare Utilization and Adverse Effects in Veterans Receiving Abiraterone Plus Prednisone with Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone (ASHP 2025) - No abstract available

Adverse events • HEOR

Tolerability of Doublet Therapy in Elderly (≥75 years) with Metastatic Prostate Cancer: A Single Centre Experience study (SIOG 2025) - "ARPIs used included 44% darolutamide , 31% abiraterone, 11% enzalutamide and 14% apalutamide. These findings highlight the feasibility and tolerability of doublet therapy in elderly patients, emphasising its role in improving outcomes in a real-world setting."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis. (PubMed, Eur Urol Focus) - "HRQoL outcomes differ across treatment strategies for mHSPC. At 12 mo, ADT + abiraterone yielded the most favourable HRQoL profile."

HEOR • Journal • Retrospective data • Review • Fatigue • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor

APRE: Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (clinicaltrials.gov) - P2 | N=130 | Recruiting | Sponsor: Martha Mims | Trial completion date: Apr 2034 ➔ Apr 2038 | Trial primary completion date: Nov 2025 ➔ Nov 2028

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) in Chinese patients with breast cancer susceptibility gene (BRCA) altered metastatic castration-sensitive prostate cancer (mCSPC): Subgroup analysis of the phase III AMPLITUDE trial (ESMO Asia 2025) - P3 | "The Chinese BRCA-positive subgroup are consistent with those reported in the overall population of the AMPLITUDE trial, supporting the utility of early genomic testing and the incorporation of NIRA+AAP as a targeted therapeutic approach for Chinese patients with BRCA gene-altered mCSPC."

Clinical • Metastases • P3 data • Breast Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD

Drug utilisation evaluation of oral anticancer therapy in a south indian cancer centre (ESMO Asia 2025) - "Among targeted therapies, Gefitinib, Osimertinib, Crizotinib, Afatinib, Lorlatinib, and Nilotinib demonstrated consumption of 30 DDDs per patient over 30 days. Lower consumptions were observed with Lenvatinib and Cabozantinib with 13.3 DDDs and 11.25 DDDs per patient respectively. In the hormonal therapy group, Letrozole, Tamoxifen, Bicalutamide, Anastrozole, Enzalutamide, and Exemestane were all prescribed in line with WHO standards (30 DDDs per patient), whereas Abiraterone exhibited lower consumption of 15 DDDs per patient. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Dose deviations occurred, though reasons were unclear and may relate to adverse effects, indication-specific or patient factors, or economic constraints. Further research is warranted..."

Oncology • Oral Cancer

Radiotherapy combined with fluzopanib and abiraterone acetate tablets (II) treatment for mCRPC (ESMO Asia 2025) - P2 | "This study aims to explore the potential efficacy and safety of the combination of fluzoparib (PARPi), abiraterone acetate (II), and radiotherapy as first-line treatment for patients with mCRPC. This multicenter, open-label, single-arm, phase II clinical study conducted in China included 40 previously untreated mCRPC (metastatic castration-resistant prostate cancer) patients aged ≥18 years. This study is currently in active enrollment stage."

Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

First-line enzalutamide vs abiraterone for castration-resistant prostate cancer: A real-world study in Japan (ESMO Asia 2025) - "This real-world analysis suggests that while ENZ was associated with longer OS in the unmatched population, there was no significant difference in OS between ENZ and ABI after adjusting for key clinical characteristics."

Clinical • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), real-world adoption of combination therapies in Australia and Asia (ESMO Asia 2025) - "Background: The addition of androgen receptor pathway inhibitors (ARPI) with or without docetaxel (DOC) to androgen deprivation therapy (ADT) has significantly improved outcomes in mHSPC...In Asia, the most common ARPI was apalutamide (41%) and abiraterone (41%). In Australia, darolutamide (30%) and enzalutamide (30%) were most used... Our real-world data demonstrates improved adoption of standard of care therapy since January 2023 in Australia and Asia. The use of ADT alone may reflect differences in the real-world population. However, the improvement seen in time to CRPC with combination therapy demonstrates the survival gains that can be achieved in the real-world setting."

Clinical • Combination therapy • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase III CAPItello-281 Chinese subgroup analysis (ESMO Asia 2025) - P3 | "rPFS and OS benefits with capi + abi vs pbo + abi were numerically greater in the Chinese subgroup vs the global population of CAPItello-281. The safety profile was also consistent with the global population and the known profiles of capi and abi. These results support the potential use of capi + abi in pts with PTEN deficient mHSPC from China mainland, Taiwan, and Hong Kong."

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. (PubMed, Int J Mol Sci) - "We detail the evidence supporting the integration of systemic agents like abiraterone, enzalutamide, and darolutamide into both hormone-sensitive and castration-resistant settings. Furthermore, we highlight the expanding role of radioligand therapies, including radium-223 and Lutetium-177-labeled PSMA-617 (Lu-PSMA-617), as well as the growing impact of PARP inhibitors in genomically selected patients. The emergence of theranostic strategies and next-generation sequencing has paved the way for personalized treatment algorithms, moving toward a truly precision oncology model in PCa. This comprehensive review synthesizes current therapeutic strategies, clinical trial evidence, and future directions aimed at optimizing outcomes and quality of life for patients with advanced prostate cancer."

Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • PTEN • TP53

PETRANHA: Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=174 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Consideration of Off-Label Therapies as Appropriate Comparator Therapy in Early Benefit Assessments in Germany Under the ALBVVG Legislation (ISPOR-EU 2025) - "The G-BA decisions regarding the choice of ACT were analyzed with a focus on the reasoning provided in the supporting documents. The selected EBA procedures showed varying outcomes: For dupilumab (eosinophilic esophagitis), an established off-label therapy was considered appropriate based on evidence-based guidelines and extensive clinical experience. For midostaurin (systemic mastocytosis), avapritinib, cladribine, and imatinib were recognized as ACT despite not all being approved for the corresponding indication, acknowledging their established role in treatment algorithms. For lisocabtagene maraleucel (various B-cell lymphomas after prior therapy), off-label use was deemed appropriate, particularly considering the disease severity and limited therapeutic alternatives for these vulnerable patients. Conversely, for talazoparib (metastatic castration-resistant prostate carcinoma), the off-label use of abiraterone acetate with prednisone/prednisolone and enzalutamide was..."

B Cell Lymphoma • Castration-Resistant Prostate Cancer • Eosinophilic Esophagitis • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Prostate Cancer • Solid Tumor